Literature DB >> 12811833

Androgen regulation of FLICE-like inhibitory protein gene expression in the rat prostate.

Kent L Nastiuk1, John W Kim, Mana Mann, John J Krolewski.   

Abstract

In hope of eventually identifying defects in human prostatic neoplasias that render them insensitive to anti-androgen therapy, we have examined the regulation of components of ligand-induced cell death pathways during castration-induced regression of the prostate. Rat prostates were obtained after surgical castration with or without subsequent androgen replacement. The mRNA levels of genes encoding components of the apoptotic pathway were measured from individual prostates. Whole prostates 1-10 days after castration did not show a significant change in mRNA levels encoding either Fas or FasL, which some studies suggest are necessary for regression to occur. However, the mRNA encoding a catalytically inactive cysteinyl aspartate-specific protease (caspase) analog, FLICE-like inhibitor protein (FLIP), decreases during the first day following castration. In the most apoptotically responsive ventral lobe of the rat prostate, the reduction in FLIP mRNA levels is evident within 12 h of castration. The mRNA levels of the principal target of FLIP inhibition, caspase-8, do not change during the period preceding the onset of detectable DNA fragmentation. Androgen administration to castrated rats reverses prostate regression, and restores FLIP mRNA to normal levels. By acting as an inhibitor of caspase-8, FLIP may protect prostatic epithelium from apoptosis. Androgen withdrawal, by reducing FLIP mRNA levels, might leave the cells vulnerable to as yet unidentified cell death signals. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12811833     DOI: 10.1002/jcp.10283

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  6 in total

1.  Doxazosin induces apoptosis of benign and malignant prostate cells via a death receptor-mediated pathway.

Authors:  Jason B Garrison; Natasha Kyprianou
Journal:  Cancer Res       Date:  2006-01-01       Impact factor: 12.701

Review 2.  Opportunities and challenges in combination gene cancer therapy.

Authors:  Kent L Nastiuk; John J Krolewski
Journal:  Adv Drug Deliv Rev       Date:  2015-12-23       Impact factor: 15.470

3.  TNF is necessary for castration-induced prostate regression, whereas TRAIL and FasL are dispensable.

Authors:  Jennifer S Davis; Kent L Nastiuk; John J Krolewski
Journal:  Mol Endocrinol       Date:  2011-02-03

4.  Induction of FLIP expression by androgens protects prostate cancer cells from TRAIL-mediated apoptosis.

Authors:  Kristin A Raclaw; Hannelore V Heemers; Emily M Kidd; Scott M Dehm; Donald J Tindall
Journal:  Prostate       Date:  2008-11-01       Impact factor: 4.104

5.  Quantitative volumetric imaging of normal, neoplastic and hyperplastic mouse prostate using ultrasound.

Authors:  Shalini Singh; Chunliu Pan; Ronald Wood; Chiuan-Ren Yeh; Shuyuan Yeh; Kai Sha; John J Krolewski; Kent L Nastiuk
Journal:  BMC Urol       Date:  2015-09-21       Impact factor: 2.264

6.  TNF signaling mediates an enzalutamide-induced metastatic phenotype of prostate cancer and microenvironment cell co-cultures.

Authors:  Kai Sha; Shuyuan Yeh; Chawnshang Chang; Kent L Nastiuk; John J Krolewski
Journal:  Oncotarget       Date:  2015-09-22
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.